Clinical and laboratory criteria for a differentiated approach to the management of children harboring opportunistic protozoa: a retrospective analysis
https://doi.org/10.33092/0025-8326mp2026.36-44
Abstract
This article substantiates a differentiated approach to the management of children with detectable commensal protists (Blastocystis spp., Dientamoeba fragilis, Entamoeba coli, Endolimax nana), based on a retrospective analysis of 325 outpatient records of patients aged 1–17 years. The relevance of the study stems from the lack of standardised diagnostic algorithms, which leads either to unwarranted antiparasitic therapy in asymptomatic carriers or to a watchful-waiting approach in symptomatic individuals.
Blastocystis spp. was identified in 54.8% of cases, with mixed infections observed in 31.4% (more frequently in girls, with age peaks at 7–10 and 15–17 years). Gastrointestinal complaints were reported in 76.9% (abdominal pain predominantly associated with Blastocystis spp., and dyspepsia and perianal pruritus with D. fragilis), allergic manifestations in 43.7%, and neurological symptoms in 28.9%. Eosinophilia >8% was recorded in 37.2% (most commonly in D. fragilis – 49.3% – and in mixed infections – 58.8%), dysbiosis in 68.3%, and chronic comorbidities in 71.4%. Prior unjustified therapy (38.5%) proved ineffective in 91.4% of cases, was accompanied by progression of dysbiosis in 71.6%, and by recurrence in 73.8%.
A five-criteria algorithm is proposed, encompassing: presence of symptoms, eosinophil count, pathogen species, status of the intestinal microbiota, and concomitant diseases. It is concluded that antiparasitic agents are indicated not merely on the basis of protist detection, but rather when clinical symptoms, eosinophilia, and microbiota disturbances coexist. Correction of dysbiosis and management of underlying pathology are mandatory in all clinically significant cases.
About the Authors
L. F. MorozovaRussian Federation
Moscow
K. A. Timonina
Russian Federation
Moscow
O. E. Morozova
Russian Federation
Moscow
K. A. Fedotova
Russian Federation
Moscow
A. A. Dmitriev
Russian Federation
Moscow
M.-M. M. Ismailov
Russian Federation
Moscow
N. A. Turbabina
Russian Federation
Moscow
M. A. Yushkevich
Russian Federation
Moscow
R. V. Polibin
Russian Federation
Moscow
A. I. Aminova
Russian Federation
Moscow
E. N. Morozov
Russian Federation
Moscow
References
1. Shasha D, Treygerman O, Levy Dahari E, Bilavsky E, Hacham D, Grupel D, Paran Y, Prajgrod G, Zacay G. High rates of Dientamoeba fragilis and Blastocystis species in children's stool but minor clinical significance. J Infect. 2024 Dec;89(6):106340. doi: 10.1016/j.jinf.2024.106340.
2. van Kalleveen MW, van Bergen M, Benninga MA, Savelkoul PHM, Plötz FB, de Meij TGJ. Diagnostic and Therapeutic Considerations Towards Dientamoeba fragilis in Children: A Survey Amongst General Practitioners and Pediatricians in the Netherlands. J Pediatr Gastroenterol Nutr. 2021 Dec 1;73(6):e121-e125. doi: 10.1097/MPG.0000000000003297.
3. Derrien M, Turroni F, Ventura M, van Sinderen D. The infant gut microbiome: a review of current knowledge and future perspectives. Gut Microbes. 2022;14(1):2149057. doi: 10.1080/19490976.2022.2149057.
4. Maleev V.V., Tokmalaev A.K., Kozhevnikova G.M., Tsvetkova N.A., Polovinkina N.A., Golub V.P., Maksimova M.S., Barysheva I.V., Konnov V.V., Kharlamova T.V. Current view on Blastocystis species: clinical forms, diagnosis and treatment // Terapevticheskii arkhiv. - 2020. - Vol. 92. - N. 11. - P. 86- 90. doi: 10.26442/00403660.2020.11.000816.
5. de Boer, M.D., Schuurs, T.A., Vermeer, M. et al. Distribution and relevance of Dientamoeba fragilis and Blastocystis species in gastroenteritis: results from a case-control study. Eur J Clin Microbiol Infect Dis 39, 197–203 (2020). doi: 10.1007/s10096-019-03710-z.
6. Ögren J, Dienus O, Löfgren S, et al. Dientamoeba fragilis prevalence coincides with gastrointestinal symptoms in children less than 11 years old in Sweden. Eur J Clin Microbiol Infect Dis. 2015;34:1995–1998. doi: 10.1007/s10096-015-2442-6.
7. Vezir S, Kaya F, Vezir E, Karaosmanoğlu N, Adiloğlu AK (2019) Evaluation of intestinal parasites in patients with chronic spontaneous urticaria in a territory hospital in Turkey. J Infect Dev Ctries 13:927–932. doi: 10.3855/jidc.11552.
8. von Huth S, Thingholm LB, Kofoed PE, Bang C, Rühlemann MC, Franke A, Holmskov U. Intestinal protozoan infections shape fecal bacterial microbiota in children from Guinea-Bissau. PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009232. doi: 10.1371/journal.pntd.0009232.
9. Krogsgaard LR, Engsbro AL, Stensvold CR, Nielsen HV, Bytzer P. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study. Clin Gastroenterol Hepatol. 2015 Mar;13(3):507-513.e2. doi: 10.1016/j.cgh.2014.07.065.
10. Alzate JF, Toro-Londoño M, Cabarcas F, Garcia-Montoya G, Galvan-Diaz A. Contrasting microbiota profiles observed in children carrying either Blastocystis spp. or the commensal amoebas Entamoeba coli or Endolimax nana. Sci Rep. 2020;10(1):15354. Published 2020 Sep 18. doi:10.1038/s41598-020-72286-y.
11. Partida-Rodriguez O, Nieves-Ramirez M, Laforest-Lapointe I, et al. Exposure to Parasitic Protists and Helminths Changes the Intestinal Community Structure of Bacterial Communities in a Cohort of Mother-Child Binomials from a Semirural Setting in Mexico. mSphere. 2021;6(4):e0008321. doi:10.1128/mSphere.00083-21.
Review
For citations:
Morozova L.F., Timonina K.A., Morozova O.E., Fedotova K.A., Dmitriev A.A., Ismailov M.M., Turbabina N.A., Yushkevich M.A., Polibin R.V., Aminova A.I., Morozov E.N. Clinical and laboratory criteria for a differentiated approach to the management of children harboring opportunistic protozoa: a retrospective analysis. Medical Parasitology and Parasitic Diseases. 2026;(2):36-44. (In Russ.) https://doi.org/10.33092/0025-8326mp2026.36-44
JATS XML







